AIDS Dementia Complex clinical trials
The registry lists 41 studies for AIDS Dementia Complex across more than 10 countries. 2 are recruiting or about to start. 29 of them are mainly about AIDS Dementia Complex (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-14.
Get an email when these change. Save the AIDS Dementia Complex studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (7) · University Hospital, Essen (3) · University of Hawaii (3) · University of Pennsylvania (3) · Johns Hopkins University (2) · Glaxo Wellcome (2) · Centaur Pharmaceuticals (2) · National Institute of Mental Health (NIMH) (2)
What is being tested here
Drugs under test in AIDS Dementia Complex studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| APP-311 C-11 | 1 | 0 | 1 |
| Zidovudine | 0 | 2 | 4 |
| Selegiline | 0 | 0 | 2 |
| Atorvastatin | 0 | 0 | 2 |
| Ferrosoferric Oxide | 0 | 0 | 2 |
| Galantamine | 0 | 0 | 1 |
| Nimodipine | 0 | 0 | 1 |
| Didanosine | 0 | 0 | 1 |
| Maraviroc | 0 | 1 | 1 |
| Cenicriviroc | 0 | 0 | 1 |
Drug classes tested here Reverse transcriptase inhibitors 7
Who these studies take
Of the 2 AIDS Dementia Complex studies recruiting now, 1 (50%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 2 (100%) | 2 (100%) |
| 65 | 2 (100%) | 2 (100%) |
| 75 | 2 (100%) | 2 (100%) |
| 85 | 1 (50%) | 1 (50%) |
Across all 41 studies, recruiting or not: 37% stop at 75 or younger and 24% at 65; 10% take children; 0% are for women only and 2% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 41 of 41. search them.
- SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral TherapyRecruitingNCT05586581Phase 1/21 country
- HIV-HEART Aging StudyRecruitingNCT043302871 country
- Rural Dementia Caregiver ProjectCompletedNCT04428112Not applicable1 country
- Effect of Galantamine on Inflammation and CognitionCompletedNCT03384784Phase 21 country
- Teleneuropsychological Intervention in Asymptomatic HIV Seropositive Patients: N&C NeuroChangeWithdrawnNCT05571761Not applicable1 country
- Exploring Racial Disparities in Sleep Health and Neurocognitive FunctionCompletedNCT04015830Not applicable1 country
- PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive SubjectsCompletedNCT03581305Phase 11 country
- SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human EncephalopathiesStatus unknownNCT02951559Phase 41 country
- Evaluation of the Role of OCT in the Detection of HIV-associated Neurocognitive DisorderCompletedNCT02431091Not applicable1 country
- Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1CompletedNCT00000738Phase 11 country
- Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia ComplexCompletedNCT00000657Phase 21 country
- A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) InfectionCompletedNCT00000702Phase 31 country
- Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV PatientsCompletedNCT00013585Phase 21 country
- An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte CountsCompletedNCT00000709Phase 31 country
- Individualized Cognitive Training in HIVCompletedNCT03122288Not applicable1 country
- Maraviroc and NeuroAIDS PathogenesisCompletedNCT02159027Phase 2/32 countries
- Intranasal Insulin for the Treatment of HANDTerminatedNCT03081117Phase 1/21 country
- Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)CompletedNCT01600170Phase 41 country
- PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)TerminatedNCT00459693Not applicable1 country
- Effect of Cenicriviroc on HIV Neurocognitive ImpairmentCompletedNCT02128828Phase 21 country
- Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1CompletedNCT004766711 country
- HIV&HEART Aging Study (12,5 Year Follow up)CompletedNCT041560481 country
- Mild Neurocognitive Disorder in HIV Infection of the BrainTerminatedNCT015477541 country
- A Prospective Observational Trial to Determine Cardiovascular Diseases in HIV-infected PatientsCompletedNCT022910811 country
- Modulation of Monocyte Activation by Atorvastatin in HIV InfectionCompletedNCT01263938Phase 41 country
- Mental Ability Challenge Study in Adults With and Without HIVCompletedNCT032444881 country
- HIV - Monotherapy in Switzerland (MOST-ch)TerminatedNCT00531986Phase 41 country
- Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive DisordersCompletedNCT01665846Phase 11 country
- Ferumoxytol-enhanced Imaging and Mapping in neuroAIDSCompletedNCT02678767Phase 21 country
- Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected IndividualsTerminatedNCT02503462Phase 41 country
- A Study of Decreased Mental Function Associated With HIVCompletedNCT00027040Not applicable1 country
- Clinical Trial of CNS-targeted HAART (CIT2)CompletedNCT00624195Phase 2/31 country
- A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)CompletedNCT00000867Phase 21 country
- The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -CompletedNCT01434563
- A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIVStatus unknownNCT01599975Phase 31 country
- A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia ComplexCompletedNCT00002246Phase 33 countries
- Minocycline for HIV+ Cognitive Impairment in UgandaTerminatedNCT00855062Phase 1/21 country
- A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular DiseasesCompletedNCT00002044Not applicable1 country
- A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia ComplexCompletedNCT00002163Phase 32 countries
- Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug TherapyCompletedNCT00002209Phase 11 country
- Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS DementiaStatus unknownNCT00002414Phase 21 country